GeoVax Labs Secures $2.5 Million in Registered Direct Offering to Advance Clinical Programs

GeoVax Labs, Inc. has entered into a securities purchase agreement with healthcare-focused institutional investors for a registered direct offering expected to generate approximately $2.5 million in gross proceeds. The company will sell 3,968,256 shares of common stock and warrants to purchase up to 11,904,768 additional shares at a combined price of $0.63 per unit. This financial infusion represents a critical step in advancing the company's pipeline of novel medical treatments.

The warrants included in the offering carry an exercise price of $0.63 per share and will become exercisable following shareholder approval, with a five-year expiration period from that approval date. Roth Capital Partners served as the sole placement agent for the transaction, which was structured under the company's existing shelf registration statement previously declared effective by the Securities and Exchange Commission. Investors can access detailed offering documents through the SEC's official website at https://www.sec.gov.

GeoVax plans to allocate the net proceeds from this financing toward advancing multiple clinical-stage product candidates. The funding will support research and development activities, manufacturing scale-up, clinical studies, and general working capital requirements. This capital comes at a pivotal moment as the company progresses several promising therapeutic programs through critical development phases.

The company's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing evaluation in three separate Phase 2 clinical trials. These trials are assessing the vaccine's potential as a primary immunization for immunocompromised patients, including those with hematologic cancers, as well as its effectiveness as a booster in specific patient populations. The company's oncology portfolio features Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.

Beyond these programs, GeoVax is developing a vaccine targeting Mpox and smallpox that may progress directly to Phase 3 clinical evaluation based on recent regulatory guidance from the European Medicines Agency. The company maintains a robust intellectual property portfolio with worldwide rights for its technologies and product candidates. Additional information about the company's clinical development progress is available at https://www.geovax.com.

This financing transaction underscores the continued investor interest in innovative biotechnology companies addressing significant unmet medical needs. The successful completion of this offering provides GeoVax with essential resources to accelerate development timelines and potentially bring important new therapeutic options to patients suffering from cancer and infectious diseases. The company's diversified pipeline positions it to address multiple substantial market opportunities in both the infectious disease and oncology therapeutic spaces.